estrogen-positive
Showing 1 - 25 of >10,000
Breast Cancer Trial in Los Angeles (Lumpectomy without sentinel node biopsy)
Recruiting
- Breast Cancer
- Lumpectomy without sentinel node biopsy
-
Los Angeles, CaliforniaCedars-Sinai Medical Center
Jan 16, 2023
Estrogen Receptor Positive Breast Cancer Trial in Edmonton (Estradiol)
Active, not recruiting
- Estrogen Receptor Positive Breast Cancer
-
Edmonton, Alberta, CanadaCross Cancer Institute
Feb 1, 2023
Breast Cancer, Brain Metastases Trial in New York (Brain Imaging with 18F-FES)
Not yet recruiting
- Breast Cancer
- Brain Metastases
- Brain Imaging with 18F-FES
-
New York, New YorkNew York-Presbyterian/Weill Cornell Medical Center
Oct 2, 2023
Low Grade Serous Ovarian Carcinoma, Adult Type Granulosa Cell Tumor Trial in Gent, Leuven, Liège (Abemaciclib, Letrozole)
Not yet recruiting
- Low Grade Serous Ovarian Carcinoma
- Adult Type Granulosa Cell Tumor
-
Gent, Oost-Vlaanderen, Belgium
- +2 more
May 12, 2023
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Trial (Giredestrant, Fulvestrant, Abemaciclib)
Not yet recruiting
- Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Giredestrant
- +6 more
- (no location specified)
Sep 26, 2023
Breast Cancer Trial in Orange City (ARV-471 (PF-07850327), Palbociclib, Letrozole)
Recruiting
- Breast Cancer
- ARV-471 (PF-07850327)
- +2 more
-
Orange City, FloridaMid Florida Hematology and Oncology Center
Jun 8, 2023
Breast Cancer Stage IV Trial in Irvine (Gallium-68)
Recruiting
- Breast Cancer Stage IV
-
Irvine, CaliforniaHoag Memorial Hospital Presbyterian
May 26, 2023
Carcinoma, Ovarian Epithelial, Low Grade Serous Adenocarcinoma of Ovary Trial in Brescia, Genova (Letrozole tablets, carboplatin
Recruiting
- Carcinoma, Ovarian Epithelial
- Low Grade Serous Adenocarcinoma of Ovary
- Letrozole tablets
- carboplatin AUC 5 and paclitaxel 175 mg/m2
-
Brescia, BS, Italy
- +1 more
Oct 26, 2022
Hormone Receptor Positive HER-2 Negative Breast Cancer Trial in Shanghai (Docetaxel, Carboplatin, Epirubicin)
Recruiting
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- Docetaxel
- +3 more
-
Shanghai, Shanghai, ChinaBreast cancer institute of Fudan University Cancer Hospital
Jun 12, 2023
Anatomic Stage IV Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8 Trial in San Francisco (Pembrolizumab,
Recruiting
- Anatomic Stage IV Breast Cancer AJCC v8
- Prognostic Stage IV Breast Cancer AJCC v8
- Pembrolizumab
- +2 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
Jan 5, 2023
Assessed by 18F-FES PET/CT in MBC With ER-positive Primary Tumor
Recruiting
- Breast Cancer
-
Shanghai, Shanghai, ChinaBiyun Wang, MD
Apr 5, 2023
Advanced ER+, HER2-Negative Breast Cancer Trial in Waltham (Elacestrant)
Completed
- Advanced ER+, HER2-Negative Breast Cancer
-
Waltham, MassachusettsRadius Pharmaceuticals, Inc.
Aug 16, 2022
Advanced or Metastatic Breast Cancer Trial in Nashville (AND019 PO QD)
Not yet recruiting
- Advanced or Metastatic Breast Cancer
- AND019 PO QD
-
Nashville, TennesseeSarah Cannon Research Institute
Jul 19, 2022
Hormone Receptor-positive Breast Cancer Trial (LACUDY)
Not yet recruiting
- Hormone Receptor-positive Breast Cancer
- (no location specified)
Dec 6, 2022
Breast Cancer Trial in Philadelphia (BPET/DBT imaging, 18F-FES)
Not yet recruiting
- Breast Cancer
- BPET/DBT imaging
- 18F-FES
-
Philadelphia, PennsylvaniaUniversity of Pennsylvania
Dec 12, 2022
Breast Cancer, Breast Cancer, Early-Onset Trial (Giredestrant, Tamoxifen)
Not yet recruiting
- Breast Cancer
- Breast Cancer, Early-Onset
- (no location specified)
Jan 18, 2023
Estrogen-receptor-positive Breast Cancer, HER2/Neu-Negative Breast Cancer, Advanced Breast Cancerv Trial in Chicago
Not yet recruiting
- Estrogen-receptor-positive Breast Cancer
- +3 more
- elacestrant, palbociclib, abemaciclib, ribociclib
-
Chicago, IllinoisNorthwestern University
Sep 25, 2023